Centre for Child and Adolescent Medicine, Clinic I, Division of Neuropaediatrics and Metabolic Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 430, 69120 Heidelberg, Germany.
Department of Neuroradiology, University of Heidelberg Medical Center, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.
J Inherit Metab Dis. 2019 Jan;42(1):117-127. doi: 10.1002/jimd.12033.
Striatal injury in patients with glutaric aciduria type 1 (GA1) results in a complex, predominantly dystonic, movement disorder. Onset may be acute following acute encephalopathic crisis (AEC) or insidious without apparent acute event.
We analyzed clinical and striatal magnetic resonance imaging (MRI) findings in 21 symptomatic GA1 patients to investigate if insidious- and acute-onset patients differed in timing, pattern of striatal injury, and outcome.
Eleven patients had acute and ten had insidious onset, two with later AEC (acute-on-insidious). The median onset of dystonia was 10 months in both groups, and severity was greater in patients after AEC (n = 8 severe, n = 5 moderate) than in insidious onset (n = 4 mild, n = 3 moderate, n = 1 severe). Deviations from guideline-recommended basic metabolic treatment were identified in six insidious-onset patients. Striatal lesions were extensive in all acute-onset patients and restricted to the dorsolateral putamen in eight of ten insidious-onset patients. After AEC, the two acute-on-insidious patients had extensive striatal changes superimposed on pre-existing dorsolateral putaminal lesions. Two insidious-onset patients with progressive dystonia without overt AEC also had extensive striatal changes, one with sequential striatal injury revealed by diffusion-weighted imaging. Insidious-onset patients had a latency phase of 3.5 months to 6.5 years between detection and clinical manifestation of dorsolateral putaminal lesions.
Insidious-onset type GA1 is characterized by dorsolateral putaminal lesions, less severe dystonia, and an asymptomatic latency phase, despite already existing lesions. Initially normal MRI during the first months and deviations from guideline-recommended treatment in a large proportion of insidious-onset patients substantiate the protective effect of neonatally initiated treatment.
1 型戊二酸血症(GA1)患者的纹状体损伤导致复杂的、主要是肌张力障碍的运动障碍。发病可在急性脑病危象(AEC)后急性发作,也可无明显急性事件而隐匿性发作。
我们分析了 21 例有症状的 GA1 患者的临床和纹状体磁共振成像(MRI)表现,以研究隐匿性和急性发作患者在纹状体损伤的时间、模式和结局上是否存在差异。
11 例患者急性发作,10 例隐匿性发作,2 例后来发生 AEC(急性发作转为隐匿性发作)。两组患者的肌张力障碍中位起病时间均为 10 个月,AEC 后(8 例重度,5 例中度)患者的严重程度大于隐匿性发作(4 例轻度,3 例中度,1 例重度)。在 6 例隐匿性发作患者中发现了偏离指南推荐的基本代谢治疗的情况。所有急性发作患者的纹状体病变广泛,10 例隐匿性发作患者中有 8 例局限于背外侧纹状体。AEC 后,2 例急性发作转为隐匿性发作的患者,除了先前存在的背外侧纹状体病变外,还出现了广泛的纹状体改变。2 例无明显 AEC 但进行性肌张力障碍的隐匿性发作患者也出现了广泛的纹状体改变,其中 1 例通过弥散加权成像显示了连续的纹状体损伤。隐匿性发作患者从检测到背外侧纹状体病变到临床表现出现潜伏期为 3.5 个月至 6.5 年。
隐匿性发作型 GA1 的特征是背外侧纹状体病变、肌张力障碍较轻和无症状潜伏期,尽管已经存在病变。在最初的几个月内 MRI 正常,以及隐匿性发作患者中有很大一部分偏离指南推荐的治疗方案,这证实了新生儿期开始治疗的保护作用。